Zenosense, Inc. (ZENO)

Take a look at some of our previously featured companies

Zenosense, Inc. (ZENO)

Postby QualityStocks » Wed Nov 08, 2017 9:39 am

Zenosense, Inc. is a healthcare technology company primarily focused on the development and commercialization of MIDS Cardiac™, a cost-effective handheld Point of Care cardiac diagnostic device used for the early, rapid detection of certain cardiac event biomarkers. Identification of these markers can significantly accelerate critical triage, diagnosis, treatment and disposition of patients reporting chest pain and those with suspected acute myocardial infarction, otherwise known as a “heart attack.”

Through the company’s joint venture ownership in MIDS Medical, the company’s unique handheld device and test strip is being developed to support high sensitivity tests to identify or discount a heart attack, with an accuracy reported at equal or better than gold standard laboratory tests, and all completed within minutes. This system is designed to meet a critical medical need and can be used with a minimum of training by any emergency room nurse or paramedic at the scene and incorporates the MIDS magnetic nanoparticle detection technology which has received patent protection in the United States and China.

The MIDS Cardiac™ device is being developed to deliver not only accuracy and rapid results, but to be easy to use and patient friendly since the test requires only a pin prick of blood. The device can be utilized at a fraction of the cost of laboratory analyzers with results that can be interpreted without specialized medical personnel.

Cardiovascular disease is the leading cause of death in the western world, accounting for more than 17 million deaths in Europe and the United States alone. Nearly 20 million patients each year visit an emergency room with reports of chest pain, with hundreds of millions spent on unnecessary admissions to the hospital. Zenosense is confident its technology platform will deliver unparalleled levels of accuracy, speed, reliability, ease of use and cost savings, making it the device of choice for hospitals, emergency rooms, medical practitioners, paramedics and in low-resource settings.

A successful development of MIDS Cardiac™ is expected to be the first step in the development of a technology platform which can serve a whole host of other critical immunoassay tests. The immunoassay market worldwide is projected to be worth $23.7 billion per year by 2019 and Zenosense believes the MIDS technology super-accurate quantitation, applicable to a new generation of high sensitivity medical tests, could be the most significant advance in diagnostic testing services in decades.
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
Site Admin
Posts: 1512
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Return to QualityStocks Previous Clients

Who is online

Users browsing this forum: No registered users and 3 guests